bremelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-04 and is reviewed periodically as new material appears.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
28 December – A new model of the largest neutron stars finds an 80–90% chance that they contain quark-matter cores. 29 December – A metascience study estimates the total amount of article processing charges paid to publish with open access in journals controlled by the five large commercial publishers from 2015–2018 to be $1.06 billion. On 12 December, it is reported that the number of paper retractions has hit a new record of over 10,000 in 2023, with around 80% coming from journals owned by Hindawi, mostly special issues overseen by guest editors. Promising innovations relating to global challenges are reported: a flying firehose robot, the Dragon Firefighter (22 Dec), completion of the first functional 105 meters tall more-modular Modvion wooden wind turbine is reported (28 Dec). Promising results of health and medical research are reported: news reports about a portable EEG helmet with significant accuracy of decoding thought words to text, DeWave (12 Dec), carrots against cancer-risk (17 Dec).
The pools of A, B, and C have delta values defined as δA, δB, and δC respectively. These values are related to the ratio of heavy to light isotopes in each pool, and are the conventional means by which scientists express the isotopic composition of materials. Importantly, δB is distinct from δb listed on the diagram, as δb is the isotopic composition of B produced from A before it mixes with the pool of B. The isotopic compositions of the pools and products are related through fractionation factors that reflect the kinetic isotope effects (KIEs) associated with each reaction. For A → B,
With no potassium intake, it is excreted at about 200 mg per day until, in about a week, potassium in the serum declines to a mildly deficient level of 3.0–3.5 mmol/L. If potassium is still withheld, the concentration continues to fall until a severe deficiency causes eventual death. The potassium moves passively through pores in the cell membrane. When ions move through ion transporters (pumps) there is a gate in the pumps on both sides of the cell membrane and only one gate can be open at once. As a result, approximately 100 ions are forced through per second. Ion channels have only one gate, and there only one kind of ion can stream through, at 10 million to 100 million ions per second. Calcium is required to open the pores, although calcium may work in reverse by blocking at least one of the pores. Carbonyl groups inside the pore on the amino acids mimic the water hydration that takes place in water solution by the nature of the electrostatic charges on four carbonyl groups inside the pore.
Sources: en.wikipedia.org
=== RNAi therapeutics === Just after Fire and Mello's ground-breaking discovery, Elbashir et al. discovered, by using synthetically made siRNA, it was possible to target the silencing of specific sequences in a gene, rather than silencing the entire gene. Only a year later, McCaffrey and colleagues demonstrated that this sequence-specific silencing had therapeutic applications by targeting a sequence from the Hepatitis C virus in transgenic mice. Since then, multiple researchers have been attempting to expand the therapeutic applications of RNAi, specifically looking to target genes that cause various types of cancer. By 2006, the first applications to reach clinical trials were in the treatment of macular degeneration and respiratory syncytial virus. Four years later the first-in-human Phase I clinical trial was started, using a nanoparticle delivery system to target solid tumors. The FDA approved the first siRNA-based drug (patisiran) in 2018. Givosiran and lumasiran later won FDA approval for the treatment of AHP and PH1 in 2019 and 2020, respectively. Inclisiran received EMA approval in 2020 for the treatment of high cholesterol and is currently under review by the FDA.
The advanced reprocessing of spent nuclear fuel is a potential key to achieve a sustainable nuclear fuel cycle and to tackle the heavy burden of nuclear waste management. In particular, the development of such advanced reprocessing systems may save natural resources, reduce waste inventory and enhance the public acceptance of nuclear energy. This strategy relies on the recycling of major actinides (Uranium and Plutonium, and also Thorium in the breeder fuel cycle) and the transmutation of minor actinides (Neptunium, Americium and Curium) in appropriate reactors. In order to fulfill this objective, selective extracting agents need to be designed and developed by investigating their complexation mechanism.
By July 2019, this has not happened, according to The Record. Critics raised concerns that Hydro One will not experience stability as Premier Ford's government has a "record of reaching in to exert control." On March 21, 2019, Minister Rickford tabled Bill 87, the Fixing the Hydro Mess Act, which was given royal assent on May 9. Bill 87 overhauled the Ontario Energy Board and eliminated the Liberal's 2017 Fair Hydro Plan which the PC's said would save $442 million. The Liberal Plan "subsidized electricity with borrowed money" in response to a "public outcry over soaring hydro rates, particularly in rural areas." The Liberals created the Ontario Power Generation Inc (OPG Trust) as the Financial Services Manager to manage the debt. Bonnie Lysyk, the Auditor General, released a special report on October 17, 2017, which said the "structure of the plan" was in violation of the provincial government's accounting rules. She said that the Plan, which committed the government to discount consumer electricity rates for ten years, would cost the province "$21 billion in interest over the next 30 years." The 2017 AG report said that it would cost $4 billion more on the $18.4 billion loan to use the Ontario Power Generation (OPG Trust) than if the province took out the loan because the province would have a lower interest rate than the OPG Trust. The Ford government said that they would maintain [the] 25 per cent time-of-use rates, that was part of the Liberal's Fair Hydro Plan.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.